Pathophysiology of Anthracycline-Induced Cardiomyopathy

  • C. W. Tomlinson
  • J. H. McNeill
  • D. V. Godin
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 65)


The pathophysiological events leading to anthracycline cardiomyopathy remain unclear in spite of intensive investigations. Major factors are thought to include stimulation of chemical processes giving rise to superoxide or hydroxyl radicals capable of causing oxidative damage to cellular membranes and thereby changes in subcellular organelles (1,2). It has also been suggested that anthracycline toxicity may arise from increased myocardial permeability resulting from induced deficiency of protective mechanisms. This could be reflected by an alterations in such enxymes as catalase, superoxide dismutase and glutathione peroxidase (3,4,5).


Sarcoplasmic Reticulum Ouabain Binding Adriamycin Treatment Ouabain Binding Site Myocardial Tissue Sample 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mimnaugh, E.G., Trush, M.A. and Gram, T.E. Biochem. Pharmac. 30:2797–2804, 1981.CrossRefGoogle Scholar
  2. 2.
    Doroshow, J.H. Cancer Res. 43:460–472, 1983.PubMedGoogle Scholar
  3. 3.
    Doroshow, J.H., Locker, G.Y. and Myers, C.E. J. Clin. Invest. 65: 128–135, 1980.CrossRefGoogle Scholar
  4. 4.
    Goodman, J. and Hochstein, P. Biochem. Biophys. Res. Commun. 77: 797–803, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Thayer, W.S. Chem. Biol. Interact. 19:265–278, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Jaenke, R.S. Lab. Invest. 30:292–304, 1974.PubMedGoogle Scholar
  7. 7.
    Gralla, E.J., Fleishman, R.W., Luthra, Y.K. and Stadnicki, S.W. Toxicology 13:263–273, 1979.PubMedGoogle Scholar
  8. 8.
    VanVleet, J.F., Ferrans, V.J. and Weirich, W.E. Am. J. Path. 99: 13–42, 1980.PubMedGoogle Scholar
  9. 9.
    Bristow, M.R., Sageman, W.S., Scott, R.H., Billingham, M.E., Bowden, E., Kernoff, R.S., Snidow, G.H. and Daniels,J.R. J. Cardiovasc. Pharmacol. 2:487–515, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Tomlinson, C.W., Godin, D.V. and Rabkin, S.W. Biochem. Pharmac. 34: 4033–4041, 1985.CrossRefGoogle Scholar
  11. 11.
    Muhammed, H., Ramasarma, T. and Kurup, C.K. Biochim. Biophys. Acta 722:43–50, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Young, D.M. Cancer Chemother. Rep. 6:159–175, 1975.Google Scholar
  13. 13.
    Goormaghtigh, E., Brasseur, R. and Ruysschaert, J.M. Biochem. Biophys. Res. Commun. 104:314–320. 1982.PubMedCrossRefGoogle Scholar
  14. 14.
    Newman, R.A., Hacker, M.P. and Krakoff, I.H. Cancer Res. 41:3483–3488, 1981.PubMedGoogle Scholar
  15. 15.
    Goldman, R., Facchinetti, T., Bach, D., Raz, A. and Shinitzky, M. Biochim. Biophys. Acta 512:254–269, 1978.PubMedCrossRefGoogle Scholar
  16. 16.
    Gosalvez, M., VanRossum, G.D.V. and Blanco, M.F. Cancer Res. 39: 257–261, 1979.PubMedGoogle Scholar
  17. 17.
    Tomlinson, C.W., McGrath, G.M. and McNeill, J.H. Can. J. Cardiol. 2: (In Press), 1986.Google Scholar
  18. 18.
    Mimnaugh, E.G., Trush, M.A. and Gram, T.E. Cancer Treat. Rep. 67: 731–733, 1983.PubMedGoogle Scholar
  19. 19.
    Olson, H.M., Young, D.M., Prieur, D.J., LeRoy, A.F. and Reagan, R.L. Am. J. Path. 77:439–454, 1974.PubMedGoogle Scholar
  20. 20.
    Rabkin, S.W. J. Cardiovasc. Pharmac. 5:848–855, 1983.CrossRefGoogle Scholar
  21. 21.
    Godin, D.V., Tuchek, J.M. and Moore, M. Can. J. Biochem. 58: 777–786, 1980.PubMedGoogle Scholar
  22. 22.
    Moore, M.M. and Godin, D.V. Can. J. Physiol. Pharmac. 62:212–223, 1984.CrossRefGoogle Scholar
  23. 23.
    Cohen, G., Dembiec, D. and Marcus, J. Analyt. Biochem. 34:30–35, 1970.PubMedCrossRefGoogle Scholar
  24. 24.
    Winterbourn, C.C., Hawkins, R.E., Brian, M. and Carrell, R.W. J. Lab. Clin. Med. 85:337–341, 1975.Google Scholar
  25. 25.
    Paglia, D.E. and Valentine, W.N. J. Lab. Clin. Med. 70:158–162, 1967.Google Scholar
  26. 26.
    Akera, T. and Cheng, V.J.K. Biochim. Biophys. Acta 470:412–423, 1977.PubMedCrossRefGoogle Scholar
  27. 27.
    Porta, E.A., Joun, N.S., Matsumara, L., Nakasone, B. and Sablan, H. Res. Commun. Chem. Path. Pharmac. 41:125–137, 1983.Google Scholar
  28. 28.
    Wang, Y.M., Madanat, F.F., Kimball, J.C. Gleiser, C.A., Ali, M.K., Kaufman, M. and VanEys, J. Cancer Res. 40:1022–1027, 1980.PubMedGoogle Scholar
  29. 29.
    Crapo, J.D., Sjostron, K. and Drew, R.T. J. Appl. Physiol. 44:364–369, 1978.Google Scholar
  30. 30.
    Tritton, T.R. and Yee, G. Science 217:248–250, 1982.CrossRefGoogle Scholar
  31. 31.
    Tomlinson, C.W. and Toleikis, P.M. Can. J. Cardiol. In Press, 1986.Google Scholar
  32. 32.
    Caroni, P., Villani, F. and Carafoli, E. Fedn. Eur. Biochem. Soc. Lett. 130:184–186, 1981.CrossRefGoogle Scholar
  33. 33.
    Harper Jr., J.R., Orringer, E.P. and Parker, J.C. Res. Commun. Chem. Path. Pharm. 26:277–284, 1979.PubMedGoogle Scholar
  34. 34.
    Lefrak, E.A., Pitha, J., Rosenheim, S. and Gottlieb, J.A. Cancer 32: 302–313, 1973.PubMedCrossRefGoogle Scholar
  35. 35.
    Singal, P.K. Persp. Cardiovasc. Res. 7:197–209, 1983.Google Scholar
  36. 36.
    Wakabayashi, T., Oki, T., Tone, H., Hirano, S. and Omori, K. J. Electron. Microsc. 29:106–118, 1980.Google Scholar
  37. 37.
    Hoffman, H., Hartl, A., Iisalo, E. and Pekkarinen, A. Act Pharmacol. Toxicol. 19:98–101, 1981.Google Scholar
  38. 38.
    Bossa, R., Galatulas, I. and Spiti, R. Pharmacology 21:400–402, 1980.PubMedCrossRefGoogle Scholar
  39. 39.
    Landolph, J.R., Bhatt, R.S., Telfer, N. and Heidelberger, C. Cancer Res. 40:4581–4588, 1980.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • C. W. Tomlinson
    • 1
    • 2
    • 3
  • J. H. McNeill
    • 1
    • 2
    • 3
  • D. V. Godin
    • 1
    • 2
    • 3
  1. 1.Departments of Medicine (Division of Cardiology), and PharmacologyUniversity of British ColumbiaVancouverCanada
  2. 2.Therapeutics, Faculty of Medicine and Division of PharmacologyUniversity of British ColumbiaVancouverCanada
  3. 3.Toxicology, Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations